{
  "id": 2683486,
  "title": "NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough",
  "url": "https://urgent.news/2026/08/21/nvax-stock-alert-biotechs-hit-post-pandemic-high-on-mrna-cancer",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T17:01:25.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/nvax-stock-alert-biotechs-hit-170125699.html"
  },
  "original_language": "en",
  "account": "Novavax (NVAX) stock has been surging due to biotech stocks hitting their highest levels since the pandemic, driven by a Moderna-Merck mRNA cancer therapy trial success. Despite Novavax not being directly involved, it benefited from sector-wide optimism. The company reported a 76% year-over-year revenue decline but topped analyst estimates with $56.7 million revenue, beating earnings estimates. Adjusted loss per share came in lower than expected at $0.32. Product sales rose 76% to $18.9 million, while Sanofi-related revenue totaled $36 million. Gross margin remained robust at 75%, and combined GAAP R&D and SG&A expenses fell 21% year-over-year. NVAX is now trading near $8.79, up over 10% in a single session and 34% YTD. The company raised its full-year 2026 revenue guidance to $235 million to $275 million, citing strengthening momentum across its partnership pipeline. Management remains optimistic about its leaner operating model and continued push toward sustainable profitability by 2028.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}